Application of Qizhi Yishen Capsule in the preparation of medicine for treating ischemic cerebrovascular disease
By digging the indications of Qixiyishen Capsules, it is used to treat ischemic stroke, significantly improve neurobehavioral dysfunction and brain tissue damage, solving the shortcomings in the treatment of ischemic stroke in the prior art, and achieving a lack of deficiency Effective improvement and safe drug application for hematologic stroke.
Patent Information
- Application Number
- CN202311038615.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-08-17
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2043-08-17
AI Technical Summary
The prior art is difficult to effectively treat ischemic stroke, especially in the acute and recovery periods, and the application of existing traditional Chinese medicine is limited, making it difficult to significantly improve neurobehavioral dysfunction and brain tissue damage.
Clinical indications of Qixiyishen Capsules, developed it for the treatment of ischemic cerebrovascular diseases, and by improving neurobehavioral dysfunction after cerebral ischemia and reperfusion, inhibiting ischemic lesions of brain histocellular cells, protecting hippocampus and Cortical neuronal cells are made of tablets, capsules, granules, pills, powders and other dosage forms.
It significantly improves neurobehavioral dysfunction in ischemic stroke, reduces the rate of cerebral infarction and atrophy, protects hippocampus and cortical neuronal cells, and has no toxic side effects, is safe and can be taken for a long time.
Smart Images

Figure CN116999501B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of traditional Chinese medicines, relates to a new use of Qizhi Yishen Capsule, and specifically relates to the use of Qizhi Yishen Capsule in preparing a medicine for treating ischemic cerebrovascular diseases. Background Art
[0002] Ischemic cerebrovascular disease is a general term for ischemic cerebrovascular diseases of varying degrees. Stroke, also known as cerebral infarction, is a group of diseases that mainly cause brain tissue damage due to rupture or blockage of brain blood vessels. It is one of the main causes of disability and death worldwide, and it has brought a huge economic burden to the medical system. The latest global stroke data released by the International Journal of Stroke in 2022 showed that Eastern Europe and China are the regions with the highest incidence and mortality rates of stroke. The annual incidence rates of men and women aged 65 and above in my country are 2.875% and 1.839%, respectively. Therefore, stroke has become a major medical problem facing my country and the world and a major challenge to health care under the trend of an aging population.
[0003] According to the different conditions of cerebrovascular lesions, stroke can be divided into two categories: hemorrhagic stroke (HS) and ischemic stroke (IS). Among them, IS is the main stroke subtype, accounting for about 87% of stroke cases, and is characterized by high morbidity, high disability rate and high mortality rate. Clinically, due to the rapid onset of IS and the narrow treatment time window, most patients are difficult to receive effective treatment. For the recovery period of IS, traditional Chinese medicine has obvious advantages. Some classic Chinese medicine prescriptions such as Buyang Huanwu Decoction and Taohong Siwu Decoction have gradually been recognized in the treatment of stroke and sequelae, and have become a hot topic in recent years.
[0004] Qizhi Yishen Capsule (QYC) is a new Chinese medicine (Class 1.1) developed by Chongqing Institute of Traditional Chinese Medicine based on the clinical experience formula of Professor Zou Yanqin, a master of traditional Chinese medicine, Qihuang Decoction. It was approved for marketing in November 2021. Qizhi Yishen Capsule is made of 10 medicinal materials including astragalus, rehmannia, Ligustrum lucidum, leech, processed bombyx batryticatus, Eupolyphaga sinensis, processed rhubarb, Gymnema sylvestre leaves, Caulis Sinomenii, and Plantago asiatica, and related excipients. It has the functions of invigorating qi and nourishing yin, removing blood stasis and dredge meridians, and is mainly used to treat qi and yin deficiency or blood stasis syndrome. Summary of the invention
[0005] In order to solve the problems in the prior art, the present invention develops new uses of Qizhi Yishen Capsule on the basis of its existing efficacy, expands its clinical indications, and provides the use of Qizhi Yishen Capsule in the preparation of drugs for treating ischemic cerebrovascular diseases.
[0006] The present invention solves the technical problem by adopting the following technical solutions:
[0007] Application of Qizhi Yishen Capsule in preparing medicine for treating ischemic cerebrovascular disease.
[0008] Furthermore, the ischemic cerebrovascular disease is ischemic stroke.
[0009] Furthermore, the drug is used to improve neurobehavioral dysfunction caused by cerebral ischemia-reperfusion.
[0010] Furthermore, the drug is used to inhibit ischemic lesion necrosis of brain tissue cells.
[0011] Furthermore, the drug is used to protect hippocampal and cortical neuronal cells.
[0012] Furthermore, the dosage forms of the drug include: tablets, capsules, granules, pills, and powders.
[0013] Compared with the prior art, the beneficial technical effects of the present invention are:
[0014] The present invention develops new effects of Qizhi Yishen Capsule on the basis of its existing effects, expands its clinical indications, and is used as a drug for treating ischemic stroke. The present invention can significantly improve neurobehavioral dysfunction, cerebral infarction rate and atrophy degree caused by cerebral ischemia-reperfusion, protect hippocampal and cortical neuronal cells, and has an improving effect on ischemic stroke (including acute and recovery phases).
[0015] The Qizhi Yishen capsule of the invention has no toxic side effects, is highly safe, can be taken for a long time, and has no drug dependence.
[0016] The above description is only an overview of the technical solution of the present invention. In order to more clearly understand the technical means of the present invention, it can be implemented according to the contents of the specification. In order to make the above and other purposes, features and advantages of the present invention more obvious and easy to understand, the specific implementation methods of the present invention are listed below. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 The present invention provides behavioral evaluation of various groups of animals in the application of the Qizhi Yishen Capsule of the present invention in the preparation of medicines for treating ischemic cerebrovascular diseases.
[0018] Figure 2 The diagram shows the TTC staining results of brain slices of each group of animals in the application of the Qizhi Yishen Capsule of the present invention in the preparation of a medicine for treating ischemic cerebrovascular disease.
[0019] Figure 3 The invention discloses the cerebral infarction rate of each group of animals in the application of the Qizhi Yishen Capsule of the present invention in the preparation of medicine for treating ischemic cerebrovascular disease.
[0020] Figure 4 The diagrams are HE staining of brain atrophy and hippocampal regions of various groups of animals when the Qizhi Yishen Capsule of the present invention is used in the preparation of a medicine for treating ischemic cerebrovascular diseases.
[0021] Figure 5 The diagram is HE staining of the cerebral cortex of each group of animals in the application of the Qizhi Yishen Capsule of the present invention in the preparation of a medicine for treating ischemic cerebrovascular disease. DETAILED DESCRIPTION
[0022] The technical solution of the present invention is further described in detail below in conjunction with the accompanying drawings and specific embodiments. It should be understood that the following embodiments are only exemplary illustrations and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are included in the scope of protection that the present invention is intended to protect.
[0023] In addition, unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or prepared by existing methods. The Qizhi Yishen Capsule used in the specific embodiment of the present invention is produced by Shandong Phoenix Pharmaceutical Co., Ltd., with the national medicine standard Z20210005.
[0024] Example 1 Effect of Qizhi Yishen Capsule on Neurobehavior
[0025] 1. Preparation of test samples
[0026] Take an appropriate amount of the contents of Qizhi Yishen Capsule, add 0.4% sodium carboxymethyl cellulose to dissolve, and prepare high (QYC-H), medium (QYC-M), and low (QYC-L) test solutions with concentrations of 0.60, 0.30, and 0.15 g / kg, respectively.
[0027] Take an appropriate amount of the content of butylphthalide soft capsules (Shijiazhuang Pharmaceutical Group Enbi Pharmaceutical Co., Ltd.), add 0.4% sodium carboxymethyl cellulose to dissolve, and prepare a positive control solution with a concentration of 10.67 mg / mL.
[0028] 2. Animal grouping
[0029] Sixty SPF-grade SD male rats (250-280 g) were selected and provided by Hunan Slake Jingda Experimental Animal Co., Ltd. [Experimental Animal Production License No.: SCXK (Xiang) 2022-0005] and kept in the experimental animal room of Chongqing Institute of Traditional Chinese Medicine [Experimental Animal Use License SYXK (Yu) 2020-0006]. The laboratory was well ventilated, with a room temperature of (25 ± 2) °C and a relative humidity of approximately (40 ± 5)%. Rats were allowed to drink water and eat freely, and standard water and diet were provided by the laboratory.
[0030] After 1 week of adaptive feeding, rats were prepared with tMCAO model according to the method of the paper MicroRNA-29b is a therapeutic target incerebral ischemia associated with aquaporin 4 [J]. J Cereb Blood Flow Metab, 2015, 35 (12): 1977-1984 (rats in the sham group underwent the same surgical procedure but without carotid artery occlusion). After surgery, Longa score was used to evaluate neurological damage and determine whether the model was successful. According to the body weight of each model rat, they were randomly divided into model group (Vehicle), QYC-H, QYC-M, QYC-L group and positive drug group (BSC). Sham-operated rats were used as control group (Sham), with 12 rats in each group. From the day of modeling, the experimental group was given corresponding drugs by gavage every day for continuous intervention for 14 days. The sham and model groups were given equal volumes of 0.4% sodium carboxymethylcellulose solution, with a drug volume of 4 mL / kg.
[0031] 3. Neurobehavioral evaluation
[0032] This example refers to the mNSS neurological deficit degree scoring, the highest score of the scoring standard is 18 points, including the following four aspects: motor test (6 points), sensory test (2 points), balance beam test (6 points) and loss of reflexes and abnormal movements (4 points). All tests are scored separately and the neurological function scores are added together, with a score range of 0 to 18 points. The lower the score, the less functional damage, that is, the lowest score of 0 points for normal function and the highest score of 18 points for the most severe functional damage.
[0033] Calculation of cerebral infarction volume: 2 hours after administration on the 14th day, rats were anesthetized with 10% sodium pentobarbital, with 6 rats in each group. The skull was opened and the brain tissue was quickly removed. The olfactory bulb, cerebellum and lower brain stem were removed. After being rinsed with cold saline, the brain tissue was placed in a brain slice mold and frozen at -20℃ for 20 minutes. The brain slices were cut into 2mm thick coronal slices along the optic chiasm coronal slices. The brain slices were immersed in 2% TCC solution, pressed with a cover glass, and stained at 37℃ in the dark for 10 minutes. The brain slices were turned over and continued to be incubated for 10 minutes. The TCC solution on the surface was absorbed by filter paper, and the brain tissue slices of each group of rats were photographed with a digital camera. The cerebral infarction volume was calculated and counted using ImagePro-Plus image analysis software. The cerebral infarction volume of rats in each group was compared using the percentage of infarction volume.
[0034] Percentage of cerebral infarction volume (%) = (sum of the white ischemic area of each slice) / (sum of the brain area of each slice) × 100%.
[0035] 4. Results
[0036] See attached Figure 1, is the behavioral score of rats in each group. It can be seen that compared with the sham operation group (Sham), the behavioral scores of rats in other groups were significantly increased, indicating that ischemia-reperfusion has caused neurological dysfunction. After 3 days of administration, compared with the model group (Vehicle), the behavioral scores of the high-dose group (QYC-H), the medium-dose group (QYC-M) and the positive drug group (BSC) of Qizhi Yishen Capsule were significantly reduced; after 7 days of administration, compared with the Vehicle group, the behaviors of the low-, medium- and high-dose groups (QYC-L, QYC-M, QYC-H) and the BSC group were significantly reduced; after 14 days of administration, the animals in each group recovered to a certain extent. Compared with the Vehicle group, the behaviors of the QYC-M, QYC-H and BSC groups were significantly reduced, and the changes in QYC-L were not significant. Therefore, Qizhi Yishen Capsule can significantly improve the neurological function of tMCAO rats, and high and medium doses of Qizhi Yishen Capsule can achieve the same effect as positive drugs.
[0037] See attached Figure 2 , 3 , respectively, are the TTC staining results of the brain sections of rats in each group and the cerebral infarction rate. Figure 2 It can be seen that compared with the Vehicle group, the ischemic volume of the QYC-L, QYC-M, QYC-H and BSC groups was significantly reduced compared with the Vehicle group. Figure 3 It can also be seen that the cerebral infarction rate of QYC-L, QYC-M, QYC-H and BSC groups was significantly lower than that of Vehicle group, and the cerebral infarction rate of QYC-M and QYC-H groups was less than 10%, which was lower than that of BSC group. It can be seen that QYC-L, QYC-M, QYC-H and BSC groups can significantly reduce the cerebral infarction rate, and the ischemic volume reduction in QYC-M and QYC-H groups is more obvious, indicating that the improvement of cerebral infarction rate in rats in the middle and high dose groups of Qizhi Yishen Capsule is more obvious than that in the positive BSC group.
[0038] Example 2 Effect of Qizhi Yishen Capsule on Pathological Morphology
[0039] Each animal in Example 1 was grouped and anesthetized with 10% sodium pentobarbital 2h after administration on the 14th day, with 6 in each group. After anesthesia, the rat was fixed to the operating table in the supine position, and the complete heart was exposed along the anterior midline thoracotomy. The infusion needle was accurately inserted into the left ventricle (apex), and the physiological saline was connected and slowly transported. At the same time, the right auricle was cut open with ophthalmic scissors to discharge the blood in the body. When the rat lung and liver color turned white, it means that the blood was washed clean; the physiological saline was replaced with 4% paraformaldehyde and continued to perfuse until the rat's whole body muscles were stiff and no longer trembled. The skull was opened and the brain tissue was quickly taken out, and the olfactory bulb, cerebellum and low brain stem were removed. The brain tissue morphology of each group of rats was taken with a digital camera, and the left brain outline was drawn and flipped to the right side using ImagePro-Plus image analysis software, and the affected side brain atrophy was counted.
[0040] The above brain tissues were fixed with formaldehyde, embedded in paraffin and then sliced (coronal plane), and then dewaxed with gradient xylene, dehydrated with gradient alcohol, stained with hematoxylin, washed with water, hydrochloric acid alcohol, washed with water, dehydrated with gradient alcohol, stained with eosin, dehydrated with alcohol, transparentized with xylene, and sealed with neutral gum to observe its pathological changes under an optical microscope.
[0041] See attached Figure 4 , Attachment Figure 5 , respectively, the brain atrophy and hippocampus HE staining of each group of animals, and the cerebral cortex HE staining of each group of animals. Figure 4 Compared with the Sham group, the Vehicle group had a significant degree of brain atrophy, the gap between neurons in the CA1 region of the hippocampus became larger, the number of neurons in the CA3 region of the hippocampus decreased, and the hippocampal nerves were damaged, indicating that the model was successfully replicated; compared with the Vehicle group, the degree of brain atrophy in tMCAO rats in the QYC-L, QYC-M, QYC-H and BSC groups was significantly reduced, and the QYC group showed a dose-dependent effect. The higher the dose, the more obvious the effect of improving brain atrophy; compared with the Vehicle group, the QYC-M, QYC-H and BSC groups could improve the nerve damage in the CA1 and CA3 regions of the hippocampus. See Appendix Figure 5 Compared with the Sham group, the cerebral cortex tissue in the Vehicle group was loose and damaged, and the neuronal cells were atrophied; compared with the Vehicle group, the cerebral cortex tissue damage in the QYC-L, QYC-M, QYC-H and BSC groups was significantly reduced, and the amount of neuronal cell atrophy was reduced. It can be seen that Qizhi Yishen Capsule has a good improvement on brain atrophy in tMCAO rats, especially the medium and high doses can protect the brain atrophy and nerve damage in tMCAO rats.
[0042] The serial numbers of the above embodiments of the present invention are only for description and do not represent the advantages or disadvantages of the embodiments.
[0043] The embodiments of the present invention are described above in conjunction with the accompanying drawings, but the present invention is not limited to the above-mentioned specific implementation methods. The above-mentioned specific implementation methods are merely illustrative and not restrictive. Under the enlightenment of the present invention, ordinary technicians in this field can also make many forms without departing from the scope of protection of the purpose of the present invention and the claims, which all fall within the protection of the present invention.
Claims
1. Application of Qizhi Yishen Capsule in the preparation of medicines for the treatment of ischemic stroke.
